Company recently announced a deal with Becton Dickinson to develop its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual market.
Rumor is that Lilly is also talking to Amarantus. Possible bidding war for "Lympro"?
The company's patented MANF technology could provide a treatent or cure for a myriad of diseases such as Alzheimer's and Parkinson's.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's advisory board.
Currently trading under a nickle. Due diligence.
get on board while it's low